Ying-Ru Lo

Ying-Ru Lo

Auto-generated profile, based on publicly available information

Ying-Ru Lo

Department of HIV/AIDS, World Health Organization, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2010 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
RGReuben Granich
Reuben Granich
SCSiobhan Crowley
Siobhan Crowley
MVMarco Antonio de Avila Vitoria
Marco Antonio de Avila Vitoria
YLYing‐Ru Lo
Ying‐Ru Lo
YSYves Souteyrand
Yves Souteyrand
BWBrian Williams
Brian Williams
In 2007 an estimated 33 million people were living with HIV; 67% resided in sub-Saharan Africa, with 35% in eight countries alone. In 2007, there were about 1.4 million HIV-positive tuberculosis cases. Globally, approximately 4 million people had been given highly active antiretroviral therapy (HAART) by the end of 2008, but in 2007, an estimated 6.7 million were still in need of HAART and 2.7 million more became infected with HIV.

5 May 2020 in Journal of Travel Medicine
Verified
Journal Article
Closed access
JWJustin Wong
Justin Wong
AAAnita B Z Abdul Aziz
Anita B Z Abdul Aziz
LCLiling Chaw
Liling Chaw
AMAbdirahman Mahamud
Abdirahman Mahamud
MGMatthew M Griffith
Matthew M Griffith
LNLin Naing
Lin Naing
We report early findings from COVID-19 cases in Brunei suggesting a remarkably high proportion of asymptomatic (12%) and presymptomatic (30%) cases. This proportion was even higher in imported cases. These have implications for measures to prevent onward local transmission and should prompt reconsideration of current testing protocols and safe de-escalation of social distancing measures.

1 January 2010 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
SKSusan C Kim
Susan C Kim
SBStephen Becker
Stephen Becker
CDCarl Dieffenbach
Carl Dieffenbach
BHBlair S Hanewall
Blair S Hanewall
CHCatherine Hankins
Catherine Hankins
MDMark R Dybul
Mark R Dybul
There are currently several ongoing or planned trials evaluating the efficacy of pre‐exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting.

28 May 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
EAElie Akl
Elie Akl
CKCaitlin Kennedy
Caitlin Kennedy
KKKelika Anne Konda
Kelika Anne Konda
CCCarlos F Caceres
Carlos F Caceres
THTara Horvath
Tara Horvath
YLYing-Ru Lo
Ying-Ru Lo
The World Health Organization (WHO) Department of HIV/AIDS led the development of public health guidelines for delivering an evidence-based, essential package of interventions for the prevention and treatment of HIV and other sexually transmitted infections (STIs) among men who have sex with men (MSM) and transgender people in the health sector in low- and middle-income countries. The objective of this paper is to review the methodological challenges faced and solutions applied during the development of the guidelines.

22 March 2022 in Vaccine
Verified
Journal Article
Open access
CSCynthia J. Snider
Cynthia J. Snider
LBLiliane Boualam
Liliane Boualam
GTGraham Tallis
Graham Tallis
Yoshihiro TakashimaYoshihiro Takashima
Yoshihiro Takashima
RARabindra Abeyasinghe
Rabindra Abeyasinghe
KFKeith Feldon
Keith Feldon
Concurrent outbreaks of circulating vaccine-derived poliovirus serotypes 1 and 2 (cVDPV1, cVDPV2) were confirmed in the Republic of the Philippines in September 2019 and were subsequently confirmed in Malaysia by early 2020. There is continuous population subgroup movement in specific geographies between the two countries. Outbreak response efforts focused on sequential supplemental immunization activities with monovalent Sabin strain oral poliovirus vaccine type 2 (mOPV2) and bivalent oral poliovirus vaccines (bOPV, containing Sabin strain types 1 and 3) as well as activities to enhance poliovirus surveillance sensitivity to detect virus circulation. A total of six cVDPV1 cases, 13 cVDPV2 cases, and one immunodeficiency-associated vaccine-derived poliovirus type 2 case were detected, and there were 35 cVDPV1 and 31 cVDPV2 isolates from environmental surveillance sewage collection sites. No further cVDPV1 or cVDPV2 have been detected in either country since March 2020. Response efforts in both countries encountered challenges, particularly those caused by the global COVID-19 pandemic. Important lessons were identified and could be useful for other countries that experience outbreaks of concurrent cVDPV serotypes.

16 December 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JOJason J. Ong
Jason J. Ong
MPMing Hui Peng
Ming Hui Peng
WWWilliam Chi Wai Wong
William Chi Wai Wong
YLYing-Ru Lo
Ying-Ru Lo
MKMichael R. Kidd
Michael R. Kidd
SJSunfang Jiang
Sunfang Jiang
Background: Primary care may be an avenue to increase coverage of HIV testing but it is unclear what challenges primary healthcare professionals in low- and middle-income countries face. We describe the HIV testing practices in community health centres (CHCs) and explore the staff’s attitude towards further development of HIV testing services at the primary care level in China. Methods: We conducted a national, cross-sectional survey using a stratified random sample of CHCs in 20 cities in 2015. Questionnaires were completed by primary care doctors and nurses in CHCs, and included questions regarding their demographics, clinical experience and their views on the facilitators and barriers to offering HIV testing in their CHC. Multivariate logistic regression was conducted to examine the association between staff who would offer HIV testing and their sociodemographic characteristics. Results: A total of 3580 staff from 158 CHCs participated. Despite the majority (81%) agreeing that HIV testing was an important part of healthcare, only 25% would provide HIV testing when requested by a patient. The majority (71%) were concerned about reimbursement, and half (47%) cited lack of training as a major barrier. Almost half (44%) believed that treating people belonging to high-risk populations would scare other patients away, and 6% openly expressed their dislike of people belonging to high-risk populations. Staff who would offer HIV testing were younger (adjusted odds ratio (aOR) 0.97 per year increase in age, 95% confidence interval (CI):0.97–0.98); trained as a doctor compared to a nurse (aOR 1.79, 95%CI:1.46–2.15); held a bachelor degree or above (aOR 1.34, 95%CI:1.11–1.62); and had previous HIV training (aOR 1.55, 95%CI:1.27–1.89). Conclusions: Improving HIV training of CHC staff, including addressing stigmatizing attitudes, and improving financial reimbursement may help increase HIV testing coverage in China.